Liposome Drug Delivery Market Size, Share and Trends 2024 to 2034

Liposome Drug Delivery Market Size and Forecast 2024 to 2034

The global liposome drug delivery market size is expected to be worth USD 5.59 billion in 2024 and is anticipated to reach around USD 13.12 billion by 2034, growing at a CAGR of 8.91% over the forecast period 2024 to 2034. The rising healthcare infrastructure and the increasing use of liposome drug delivery method in the various disease such as cancer, skin infraction and other infectious disease are driving the growth of the market.

Liposome Drug Delivery Market Key Takeaways

• North America dominated the liposome drug delivery market with the largest market share of 41% in 2023.
• Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
• By liposome structure, the unilamellar liposomes segment dominated the market in 2023.
• By product, the liposomal doxorubicin segment contributed the biggest market share of 36% in 2023.
• By technology, the stealth liposome technology segment accounted for a considerable market share of 43% in 2023.
• By application, the cancer therapy segment generated the highest market share of 54% in 2023.
• By end-user, the hospitals segment dominated the market in 2023.

U.S. Liposome Drug Delivery Market Size and Growth 2024 to 2034

The U.S. liposome drug delivery market size was exhibited at USD 1.58 billion in 2023 and is projected to be worth around USD 4.11 billion by 2034, poised to grow at a CAGR of 9.07% from 2024 to 2034.

North America dominated the liposome drug delivery market in 2023. The growth of the market is attributed to the rising advancement in the healthcare and pharmaceutical sectors, and the support of government facilities and policies towards medical infrastructure drives the growth of the healthcare sector. The rising burden of cancer cases in the United States and Canada is driving the demand for precise oncology treatment, which boosts the growth of liposome drug delivery and other oncology drugs and delivery systems. Additionally, the availability of major healthcare providers and medical technology leaders is also driving the expansion of the liposome drug delivery market across the region.

• The CDC’s National Center for Health Statistics stated that there are 107,543 deaths were caused by the overdose of drugs in the United States during 2023, with a 3% decrease from 2022.
• In August 2024, the Food and Drug Administration approved chemotherapy containing durvalumab (Imfinzi, AstraZeneca) with platinum as neoadjuvant treatment, with the single-agent durvalumab as surgery after treatment for adults with the condition of non-small cell lung cancer and anaplastic lymphoma kinase (ALK) or epidermal growth factor receptor (EGFR) mutations. 

Asia Pacific is anticipated to grow at the fastest rate during the forecast period. The growth of the market is attributed to the rising population and the increasing availability of the geriatric population, which is more likely to get affected by cancer and another chronic diseases that drives the demand for liposome drug delivery for efficient treatment procedures in patients that contribute in the growth of the liposome drug delivery market in the region.

Market Overview

Liposomes are known for their carrier of the nanocarrier for the potentially active hydrophilic and hydrophobic due to their higher biodegradability, biocompatibility, and low immunogenicity. The liposomes are efficiently used in increasing drug solubility, controlled distribution, and capacity for surface modifications for prolonged, targeted, and sustained release. Liposome drug delivery is used for the treatment of several diseases, such as fungal infections, cancer, viral infections, and others. It minimizes the side effects of the drugs and residence time in target cells. The rising cases of chronic illness in the population are driving the demands for the liposome drug delivery market.

Liposome Drug Delivery Market Trends

• Recent trends in drug delivery systems include:
• Ultra Deep Freeze Drug Delivery Systems
• The Continuing Homecare Trend
• Wearable Drug Delivery Systems
• Smart Drug Delivery Systems
• Sustainability in Drug Delivery Systems

How Can AI Impact the Liposome Drug Delivery Market?

Artificial intelligence transforms the various sectors and their operations. The adaptation of AI in the healthcare sector transforms the overall healthcare, pharmaceutical, and biotechnology fields. It provides powerful insights into biotechnology, including predictive modeling, data analytics, and process optimization. AI enhances healthcare operations from drug discovery to personalized diagnosis and medicine. AI works to accelerate drug discovery by optimizing drug formulations, predicting the biological activity of compounds, and identifying potential side effects. The integration enhanced the efficiency of the drug discovery process and drove the research and development process in biotechnology, helping to drive innovations in the healthcare sector.

• In April 2024, Xaira Therapeutics launched the mission to help re-engineer developing and discovering medicines through the end-to-end application of emerging AI technologies. Xaira brings expansive data generation to power new models, advanced machine learning research, and robust therapeutic product development.

Liposome Drug Delivery Market Growth Factors

• The rising population and the increasing prevalence of chronic illnesses such as cancer, diabetes, cardiovascular disease, respiratory illness, and others are driving the demand for an efficient healthcare system.
• The rise in the healthcare and pharmaceutical industry and the advancement in healthcare technologies are driving the expansion of drug and treatment procedure development, which is anticipated to drive the growth of the market.
• The rising cases of cancer in the worldwide population due to the rising environmental conditions, genetics, hygiene, acceptance of the sedentary lifestyle such as acceptance of the rising consumption of alcohol, smoking which reduces the immune system and body more prone to disease.
• The increasing investment in the development of liposome drug delivery and the rising collaboration between pharmaceutical leaders for the development and innovations in drug delivery boosts the expansion of the liposome drug delivery market.
• The liposome drugs are chemotherapy drugs that help protect healthy tissues from infection; thus, the rising burden of cancer and the global demand for chemotherapy and the treatment of cancer are driving the growth of the market.

Market Scope

Market Dynamics

Driver

The rising adoption of liposome drugs for skin

The rising younger population and the rising awareness of skincare are driving the demand for active chemicals that help rejuvenate skin and enhance the skincare process. Where liposomes are small spherical shapes that help in skin care and reduce the side effects of cosmetics products. Liposome delivery is the method of cosmetic formulation. The liposome's properties, such as penetration, stability, and effectiveness of active substances, enhanced the quality and effectivity of the product. Liposomes are used in a variety of skincare owing to their distinct structure. Its higher encapsulation properties benefit the skincare, increase the penetration into the skin, and increase efficiency.

• In February 2023, Decorté Cosmetics will extend the range of its bestselling Liposome skin care with a new eye serum to enhance its presence in the high-end beauty market of Asia Pacific, Europe, and America.

Restraint

High cost

The increased cost of treatment, the possibility of instability, poor manufacturing process, and increased intracellular delivery are some of the associated limitations on the growth of the liposome drug delivery market.

Opportunity

The increase in demand for advanced drugs and treatment procedures

The increasing prevalence of chronic diseases and the rising demand for precise drug delivery methods for better treatment drive the growth opportunity for the liposome drug delivery market. The rising adaptation of the modern drug delivery procedure with reduced side effects and unparalleled accuracy in the treatment procedures. Liposomes have unique properties like encapsulation within the bilayer structure, which works as the shield of the drugs from degradation. Liposomes are highly effective for targeting tissues or specific cells.

Liposome Structure Insights

The unilamellar liposomes segment dominated the liposome drug delivery market in 2023. The increased adoption of the unilamellar liposome in oncology treatment is owing to its higher accuracy in the format of dosage; its single-layer lipid transforms the drug administration process by encapsulating pharmaceutical agents with accuracy. They are mostly used in the study of biological systems and mimic cell membranes. The unilamellar liposome is divided into three parts that are small unilamellar liposomes/vesicles (SUVs) with a 20–100 nm size range, giant unilamellar liposomes/vesicles (GUVs) with a 1–200 μm size range, and large unilamellar liposomes/vesicles (LUVs) with a 100–1000 nm size range. The unilamellar liposomes are highly used in medical studies and are used to provide tools for studying protein localization in the plasma membrane, membrane fusion, study ion channels, etc.

Product Insights

The liposomal doxorubicin segment held a dominant presence in the liposome drug delivery market in 2023. The liposomal doxorubicin is also known as the Caelyx; it is the type of chemotherapy that is used in the treatment procedure of the patient with cancer disease. It is a chemotherapy drug known as the anthracycline.

It is used in cancer treatment to restrict the expansion of the enzyme named topoisomerase 2, which helps in the expansion of the cancer cells. It contained tiny spheres called pegylated liposomes. The rising cases of cancer patients worldwide are driving the demand for treatment and chemotherapy, which boosts the demand for liposomal doxorubicin.

Technology Insights

The stealth liposome technology segment accounted for a considerable share of the liposome drug delivery market in 2023. The Stealth liposome technology is the revolution in pharmaceutical operations and in the treatment procedures related to oncology. The stealth liposome excels in evading immune detection, incorporating polyethylene glycol (PEG) coatings, extending circulation, and increasing drug targeting is reshaping the oncology treatment procedures. The stealth liposome technology helps in enhancing the personalized medicine trajectory and enhances medicinal efficiency, patient-centric treatment, and targeted therapies.

Application Insights

The cancer therapy segment registered its dominance over the global liposome drug delivery market in 2023. Liposome drugs are highly beneficial in the treatment of cancer; they directly target cancer cells with greater precision with lower side effects. They are used in the treatment by delivering drugs through chemotherapy. The global rise in cancer patients and the disease being the second leading cause of death and expanding as the major health issue in the population drives the demand for an efficient cancer diagnostics process. There are several types of cancer found worldwide. The changing lifestyle preferences, environmental issues, and genetics are the major causes of cancer. The rising investment in cancer drug development drives the demand for liposome drug delivery.

• Spending on cancer medicines is anticipated to reach $75 billion by 2027, an increase from $196 billion in 2022. The global cases of patients being treated have increased by an average of 5% annually over the last five years.
• Several emerging biopharma companies drive the innovations in oncology in 2022 and hold for 71% of the pipeline.

End-user Insights

The hospitals segment dominated the liposome drug delivery market in 2023. The increasing preference for getting proper diagnostics and treatment of several kinds of diseases in the hospitals due to the higher availability of skilled and professional healthcare workers and healthcare infrastructure such as medical devices and drugs boosts the preference of the hospital segment. Hospitals are pursuing rising investment in the healthcare infrastructure and technological advancements to enhance the efficiency of healthcare operations.

Liposome Drug Delivery Market Companies

• Johnson & Johnson Services, Inc.
• Gilead Sciences, Inc.
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• Teva Pharmaceutical Industries Ltd
• Janssen Pharmaceuticals, Inc.
• CELSION Corporation
• Abbott
• Ipsen Pharma
• Spectrum Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited.

Recent Developments

• In April 2022, Innocan Pharma Corporation proudly announced the Company submitted its letter of application for a Pre-IND meeting for the first phase of the FDA approval process for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain in the United States.
• In May 2023, Gencor and Pharmacy Biotechnologies announced the launch of the latest liposome tech with its scientifically proven PlexoZome technology. It is the advanced targeted delivery liposomal technology for liquid formulations specially developed for fully customizable and stable liposomal ingredients.

Segments Covered in the Report

By Liposome Structure

• Unilamellar Liposome
• Small
• Large
• Multilamellar Liposome
• Others

By Product

• Liposomal Doxorubicin
• Liposomal Paclitaxel
• Liposomal Amphotericin B
• Others

By Technology

• Stealth Liposome Technology
• Non-PEGylated Liposome Technology
• DepoFoam Liposome Technology

By Application

• Fungal Disease
• Pain Management
• Cancer Therapy
• Viral Vaccine
• Photodynamic Therapy

By End-User

• Hospitals
• Specialty Centers
• Ambulatory Surgical Centers
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa